Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Secretoneurin as a Novel Biomarker of Cardiovascular Episodes: Are We There Yet? A Narrative Review

J. Plášek, M. Lazárová, J. Dodulík, P. Šulc, D. Stejskal, Z. Švagera, F. Všianský, J. Václavík

. 2022 ; 11 (23) : . [pub] 20221203

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22031127

Secretoneurin (SN) is a 33 amino-acid evolutionary conserved neuropeptide from the chromogranin peptide family. SN's main effects may be cardioprotective and are believed to be mediated through its inhibition of calmodulin-dependent kinase II (CaMKII), which influences intracellular calcium handling. SN inhibition of CaMKII suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. This action may reduce the risk of ventricular arrhythmias and calcium-dependent remodelling in heart failure. SN is also involved in reducing the intracellular reactive oxygen species concentration, modulating the immune response, and regulating the cell cycle, including apoptosis. SN can predict mortality in different disease states, beyond the classical risk factors and markers of myocardial injury. Plasma SN levels are elevated soon after an arrhythmogenic episode. In summary, SN is a novel biomarker with potential in cardiovascular medicine, and probably beyond.

000      
00000naa a2200000 a 4500
001      
bmc22031127
003      
CZ-PrNML
005      
20230127131039.0
007      
ta
008      
230119s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jcm11237191 $2 doi
035    __
$a (PubMed)36498765
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Plášek, Jiří $u Dept. of Internal Medicine and Cardiology, University Hospital Ostrava, 70800 Ostrava, Czech Republic $u Research Center for Internal and Cardiovascular Diseases, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $1 https://orcid.org/0000000251839557
245    10
$a Secretoneurin as a Novel Biomarker of Cardiovascular Episodes: Are We There Yet? A Narrative Review / $c J. Plášek, M. Lazárová, J. Dodulík, P. Šulc, D. Stejskal, Z. Švagera, F. Všianský, J. Václavík
520    9_
$a Secretoneurin (SN) is a 33 amino-acid evolutionary conserved neuropeptide from the chromogranin peptide family. SN's main effects may be cardioprotective and are believed to be mediated through its inhibition of calmodulin-dependent kinase II (CaMKII), which influences intracellular calcium handling. SN inhibition of CaMKII suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. This action may reduce the risk of ventricular arrhythmias and calcium-dependent remodelling in heart failure. SN is also involved in reducing the intracellular reactive oxygen species concentration, modulating the immune response, and regulating the cell cycle, including apoptosis. SN can predict mortality in different disease states, beyond the classical risk factors and markers of myocardial injury. Plasma SN levels are elevated soon after an arrhythmogenic episode. In summary, SN is a novel biomarker with potential in cardiovascular medicine, and probably beyond.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Lazárová, Marie $u Dept. of Internal Medicine and Cardiology, University Hospital Ostrava, 70800 Ostrava, Czech Republic
700    1_
$a Dodulík, Jozef $u Dept. of Internal Medicine and Cardiology, University Hospital Ostrava, 70800 Ostrava, Czech Republic
700    1_
$a Šulc, Patrik $u Dept. of Internal Medicine and Cardiology, University Hospital Ostrava, 70800 Ostrava, Czech Republic
700    1_
$a Stejskal, David $u Institute of Laboratory Medicine, University Hospital Ostrava, 70800 Ostrava, Czech Republic $u Institute of Laboratory Medicine, University of Ostrava, 70103 Ostrava, Czech Republic
700    1_
$a Švagera, Zdeněk $u Institute of Laboratory Medicine, University Hospital Ostrava, 70800 Ostrava, Czech Republic $u Institute of Laboratory Medicine, University of Ostrava, 70103 Ostrava, Czech Republic
700    1_
$a Všianský, František $u Institute of Laboratory Medicine, University Hospital Ostrava, 70800 Ostrava, Czech Republic
700    1_
$a Václavík, Jan $u Dept. of Internal Medicine and Cardiology, University Hospital Ostrava, 70800 Ostrava, Czech Republic $u Research Center for Internal and Cardiovascular Diseases, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic
773    0_
$w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 11, č. 23 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36498765 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230127131030 $b ABA008
999    __
$a ok $b bmc $g 1889375 $s 1182460
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 11 $c 23 $e 20221203 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
LZP    __
$a Pubmed-20230119

Najít záznam

Citační ukazatele

Možnosti archivace